{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:49:41Z","timestamp":1781279381062,"version":"3.54.1"},"reference-count":36,"publisher":"Japanese Society of Toxicologic Pathology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Toxicol Pathol"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1293\/tox.2013-0033","type":"journal-article","created":{"date-parts":[[2014,1,5]],"date-time":"2014-01-05T23:02:43Z","timestamp":1388962963000},"page":"31-42","source":"Crossref","is-referenced-by-count":8,"title":["Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT&lt;sub&gt;1B&lt;\/sub&gt; Inhibitor"],"prefix":"10.1293","volume":"27","author":[{"given":"Jane C.F.","family":"Chang","sequence":"first","affiliation":[{"name":"AstraZeneca R&D"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D"},{"name":"Cubist Pharmaceuticals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schroeder","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D"},{"name":"EMD Serono"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Wright","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Westwood","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Berg","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D"},{"name":"MPA, L\u00e4kemedelsverket"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"121","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zhang M, Zhou D, Wang Y, Maier DL, Widzowski DW, Sobotka-Briner CD, Brockel BJ, Potts WM, Shenvi AB, Bernstein PR, and Pierson ME. Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine1B receptor antagonist. J Pharmacol Exp Ther. 339: 567\u2013578. 2011.","DOI":"10.1124\/jpet.110.174433"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fink KB, and G\u00f6thert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev. 59: 360\u2013417. 2007.","DOI":"10.1124\/pr.59.07103"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Moret C, and Briley M. The possible role of 5-HT<sub>1B\/1D<\/sub> receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol. 404: 1\u201312. 2000.","DOI":"10.1016\/S0014-2999(00)00581-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Slassi A. Recent advances in 5-HT<sub>1B\/1D<\/sub> receptor antagonists and agonists and their potential therapeutic applications. Curr Top Med Chem. 2: 559\u2013574. 2002.","DOI":"10.2174\/1568026023393903"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Varn\u00e4s K, Nybert S, Karlsson P, Pierson ME, K\u00e5gedal M, Csel\u00e9nyi Z, McCarthy D, Xiao A, Zhang M, Halldin C, and Farde L. Dose-dependent binding of AZD3783 to brain 5- HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369. Psychopharmacology. 213: 533\u2013545. 2011.","DOI":"10.1007\/s00213-011-2165-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Peroutka SJ, and Howell T. The molecular evolution of G protein-coupled receptors. Neuropharmacology. 33: 319\u2013324. 1994.","DOI":"10.1016\/0028-3908(94)90060-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. L\u00fcllmann H, L\u00fcllmann-Rauch R, Wassermann O, and de la Lglesia FA. Drug-induced phospholipidosis. CRC Crit Rev Toxicol. 2: 185\u2013218. 1975.","DOI":"10.1080\/10408447509164014"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kodavanti UP, and Mehendale HM. Cationic amphiliphilic drugs and phospholipid storage disorder. Pharmacol Rev. 42: 327\u2013354. 1990.","DOI":"10.1016\/S0031-6997(25)00049-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Reasor MJ. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol Appl Pharmacol. 97: 47\u201356. 1989.","DOI":"10.1016\/0041-008X(89)90054-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Reasor MJ, and Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med (Maywood). 226: 825\u2013830. 2001.","DOI":"10.1177\/153537020122600903"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, and Zimmer HJ. Amidarone hepatotoxicity: prevalence and clinicopathologic correlation among 104 patients. Hepatology. 9: 679\u2013685. 1989.","DOI":"10.1002\/hep.1840090504"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gonzalez-Rothi RJ, Zander DS, and Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest. 107: 1763\u20131765. 1995.","DOI":"10.1378\/chest.107.6.1763"},{"key":"13","unstructured":"13. Laplane D, and Bousser MG. Polyneuropathy during perhexiline maleate therapy. Int J Neurol. 15: 293\u2013300. 1981."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. M\u00e4ntyj\u00e4rvi M, Tuppurainen K, and Ik\u00e4heimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 42: 360\u2013366. 1998.","DOI":"10.1016\/S0039-6257(97)00118-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Reasor MJ, Hastings KL, and Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 5: 567\u2013583. 2006.","DOI":"10.1517\/14740338.5.4.567"},{"key":"16","unstructured":"16. FDA. The pink sheet: Safety a concern. FDA phospholipidosis guidance being developed. Vol. 66, No. 133, pp. 24. 2004."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Morelli JK, Buehrle M, Pognan F, Barone LR, Fieles W, and Ciaccio PJ. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol. 22: 15\u201327. 2006.","DOI":"10.1007\/s10565-006-0176-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hruban Z. Pulmonary changes induced by amphiphilic drugs. Environ Health Perspect. 16: 111\u2013118. 1976.","DOI":"10.1289\/ehp.7616111"},{"key":"19","unstructured":"19. L\u00fcllmann-Rauch R. Drug-induced lysosomal storage disorders. Front Biol. 48: 49\u2013130. 1979."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Robison RL, Visscher GE, Roberts SA, Engstrom RG, Hartman HA, and Ballard FH. Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug. Toxicol Pathol. 13: 335\u2013348. 1985.","DOI":"10.1177\/019262338501300410"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, and Adams SP. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem Res Toxicol. 23: 749\u2013755. 2010.","DOI":"10.1021\/tx9003825"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Haywood R. The eye. In: Target Organ Toxicity, Vol. II. GM Cohen (ed). CRC Press, Boca Raton. 109\u2013124. 1986.","DOI":"10.4324\/9780429290299-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Drenckhahn D, and L\u00fcllmann-Rauch R. Drug-induced retinal lipidosis: differential susceptibilities of pigment epithelium and neuroretina toward several amphiphilic cationic drugs. Exp Mol Pathol. 28: 360\u2013371. 1978.","DOI":"10.1016\/0014-4800(78)90010-2"},{"key":"24","unstructured":"24. Summary Basis of Approval, FDA, NDA18-936 (Fluoxetine) Dec 7, 1987."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bicer S, Fuller GA, Wilkie DA, Yamaguchi M, and Hamlin RL. Amidarone-induced keratopathy in healthy dogs. Vet Ophthalmol. 5: 35\u201338. 2002.","DOI":"10.1046\/j.1463-5224.2002.00208.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gwaltney-Brant SM, Albretsen JC, and Khan SA. 5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989-1999). J Am Vet Med Assoc. 216: 1937\u20131940. 2000.","DOI":"10.2460\/javma.2000.216.1937"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mohammad-Zaddeh LF, Moses L, and Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Therap. 31: 187\u2013199. 2008.","DOI":"10.1111\/j.1365-2885.2008.00944.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cartwright ME, Petruska J, Arezzo J, Frank D, Litwak M, Morrissey RE, MacDonald J, and Davis TE. Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects. Toxicol Pathol. 37: 902\u2013910. 2009.","DOI":"10.1177\/0192623309348521"},{"key":"29","unstructured":"29. Sadrich N. The regulatory challenge of drug-induced phospholipidosis. Presented in: FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting, April 14, 2010."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Spaet RH, Sullivan DJ, and Diener RM. Occurrence of myeloid bodies in rats following two-year administration of imipramine hydrochloride. Toxicol Pathol. 11: 3\u201311. 1983.","DOI":"10.1177\/019262338301100102"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. L\u00fcllmann-Rauch R, and N\u00e4ssberger L. Citalopram-induced generalized lipidosis in rats. Acta Pharmacol Toxicol (Copenh). 52: 161\u2013167. 1983.","DOI":"10.1111\/j.1600-0773.1983.tb01080.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nonoyama T, and Fukuda R. Drug-induced phospholipidosis \u2013 pathological aspects and its prediction. J Toxicol Pathol. 21: 9\u201324. 2008.","DOI":"10.1293\/tox.21.9"},{"key":"33","unstructured":"33. Summary Basis of Approval, FDA, NDA 20-822 (Citalopram Hydrobromide) June 2, 1998."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wada R, Tifft CJ, and Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA. 97: 10954\u201310959. 2000.","DOI":"10.1073\/pnas.97.20.10954"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kannan R, Sarma SM, Guha M, and Venkataraman K. Tissue drug accumulation and ultrastructural changes during amiodarone administration in rats. Fundam Appl Toxicol. 13: 793\u2013803. 1989.","DOI":"10.1016\/0272-0590(89)90334-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Leblanc NL, Steven RL, and Bentley E. Ocular lesions associated with systemic hypertension in dogs: 65 cases (2005-2007). J Am Vet Med Assoc. 238: 915\u2013921. 2011.","DOI":"10.2460\/javma.238.7.915"}],"container-title":["Journal of Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/27\/1\/27_2013-0033\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:12:15Z","timestamp":1746097935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/27\/1\/27_2013-0033\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1293\/tox.2013-0033","relation":{},"ISSN":["0914-9198","1881-915X"],"issn-type":[{"value":"0914-9198","type":"print"},{"value":"1881-915X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}